References
- Walsh PC. Human benign prostatic hyperplasia: etio-logical considerations. Prog Clin Biol Res 1984; 145: 1–25.
- Berry SJ, Coffey DS, Walsh PC, Ewing LL. The devel-opment of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474–9.
- Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 1991; 145: 405–9.
- Bosch it, Hop WC, Niemer AQ, Bangma CH, Kirkels WJ, Schroeder FH. Parameters of prostate volume and shape in community based population of men 55 to 74 years old. J Urol 1994; 152: 1501–5.
- Boyle P, Gould AL, Roehrbom CG. Prostate volume predicts outcome of treatment of benign prostatic hyper-plasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398–405.
- Guess HA. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1995; 22: 247–61.
- Collins GN, Lee RJ, McKelvie GB, Rogers AC, Hehir M. Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Br J Urol 1993; 71: 445–50.
- Isaacs JT. Etiology of benign prostatic hyperplasia. Eur Urol 1994; 25 (Suppl 1): 6–9.
- Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Natural history of prostatism: risk factors for acute urinary retention. Urology 1997; 158: 481–7.
- Roehrbom CG, McConnell J, Bonilla J, Rosenblatt S, Hudson PB, Malek GH, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000; 163: 13–20.
- Uygur MC, Erol D, Cetinkaya M, Gungen Y, Laleli Y, Altug U. Analysis of prostate-specific antigen values from 4,846 Turkish men with symptomatic benign prostatic hyperplasia. The correlation between prostate-specific antigen and age. Eur Urol 1997; 32: 416–9.
- Morote J, Encabo G, Lopez M, de Torres IM. Prediction of prostate volume based on total and free serum prostate-specific antigen: is it reliable? Eur Urol 2000; 38: 91–5.
- Ezz el Din K, Kiemeney LA, Wildt MJ, Debruyne FM, de la Rosette JJ. Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology 1996; 48: 393–7.
- Boci R, Fall M, Walden M, Knutson T, Dahlstrand C. The home uroflowmetry-improved accuracy in outflow assessment. Neurourol Urodyn 1998; 18: 25–32.
- Barry MJ, Cockett AT, Holtgrewe HL, McConell JD, Sihelnik SA, Winfield HN. Relationship of symptoms of prostatism to commonly used physiological and anato-mical measures of the severity of benign prostatic hyperplasia. J Urol 1993; 150: 351–8.
- Collins GN, Lee RJ, Russel EB, Raab GM, Hehir M. Ultrasonically determined patterns of enlargement in benign prostatic hyperplasia. Br J Urol 1993; 71: 451–6.
- Siroky MB, Olsson CA, Krane RJ. Clinical correlation. The flow rate nomogram. II. J Urol 1980; 123: 208–10.
- Eckhardt MD, van Venrooij GE, Boon TA. Symptoms, prostate volume, and urodynamic findings in elderly male volunteers without and with LUTS and in patients with LUTS suggestive of benign prostatic hyperplasia. Urology 2001; 58: 966–71.
- Zackrisson B, Hugosson J, Aus G. Transrectal ultrasound anatomy of the prostate and seminal vesicles in healthy men. Scand J Urol Nephrol 2000; 34: 175–80.
- Hendrikx AJ, Doesburg WH, Reintjes AG, van Helvoort-van Dommelen CA, Hofmans PA, Debruyne FM. Deter-mination of prostatic volume by ultrasonography. A useful procedure in patients with prostatism? Urology 1989; 33: 336–9.
- Watanabe H. Natural history of benign prostatic hypertrophy. Ultrasound Med Biol 1986; 12: 567–71.
- Venrooij GE, Boon TA. The value of symptom score, quality of life score, maximal urinary flow rate, residual volume and prostate size for the diagnosis of obstructive benign prostatic hyperplasia: a urodynamic analysis. J Urol 1996; 155: 2014–8.
- Eckhardt MD, Venrooij GE, Boon TA. Symptoms and quality of life versus age, prostate volume, and uro-dynamic parameters in 565 strictly selected men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2001; 57: 695–700.
- Knutson T, Schafer W, Fall M, Pettersson S, Dahlstrand C. Can urodynamic assessment of outflow obstruction predict outcome from watchful waiting? Scand J Urol Nephrol 2001; 35: 463–9.
- Roehrbom CG, Boyle P, Gould L, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999; 53: 581–8.